Car T-Cell Therapy

The microbiome is linked to myriad processes in human health and disease.

Healio spoke with Chakra Chaulagain, MD, about updated safety results from the KarMMa-3 trial presented at ASH 2023.

In this episode, host Shikha Jain, MD, speaks with St. Jude’s Steven Gottschalk, MD, and Paulina Velasquez, MD, about the evolution of bone marrow transplant and cell therapy, increasing accessibility to CAR T-cell therapy and more.

In this video, Brian T. Hill, MD, PhD, discusses results of the phase 2 PILOT study of lisocabtagene maraleucel as second-line therapy for relapsed/refractory diffuse large B-cell lymphoma.

SAN DIEGO — All 38 patients with heavily pretreated multiple myeloma responded to an investigational chimeric antigen receptor T-cell therapy, results of a phase 1 study presented at ASH Annual Meeting and Exhibition showed.

SAN DIEGO — Patients with relapsed large B-cell lymphoma who achieved a complete remission had a reduced relapse rate and improved PFS with autologous transplant, according to study findings presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Individuals with private insurance that requires a signed agreement before receiving chimeric antigen receptor T cells had significant delays in treatment, study results presented at ASH Annual Meeting and Exposition showed.

Chimeric antigen receptor T cells have improved survival rates as second-line therapy for individuals with high-risk diffuse large B-cell lymphoma, but available therapies lack cost-effectiveness at current prices, study results showed.

The FDA published a safety advisory on the risk of T-cell malignancies among individuals receiving autologous chimeric antigen receptor T-cell therapy for the treatment of certain blood cancers.

This blog post provides answers to important questions about the upcoming respiratory viral seasons.